Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10
Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10
布魯克林資本以買入評級啓動對Immunic的報道,宣佈目標股價爲10美元
Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $10.
布魯克林資本分析師泰勒·布西安以買入評級啓動了對Immunic(納斯達克股票代碼:IMUX)的報道,並宣佈目標股價爲10美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。